ANI Pharmaceuticals CFO sells 7,312 shares

ANI Pharmaceuticals senior vice president and CFO Stephen P. Carey reported both an option exercise and share sales.

Accepted by SEC EDGAR 03/05/2026 - 05:46 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

ANI Pharmaceuticals senior vice president and CFO Stephen P. Carey reported both an option exercise and share sales. He exercised options for 3,312 shares at $49.51 per share, then sold a total of 7,312 common shares in open‑market trades at prices around $75.42–$75.56. Following these transactions, he directly holds 185,543 shares of common stock and 9,938 stock options.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 4 txns

Insider CAREY STEPHEN P.

Role SVP & CFO

Sold 7,312 shs ($552K)

Approx. gross sale proceeds $552K

Approx. exercise cost $164K

Share of Position Sold 3.8%

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	3,312	$49.51	$164K
Exercise	Common Stock	3,312	$49.51	$164K
Sale	Common Stock	3,312	$75.42	$250K
Sale	Common Stock	4,000	$75.56	$302K

Holdings After Transaction: Stock Option (right to buy) — 9,938 contracts (Direct); Common Stock — 185,543 shares (Direct)

Holdings Before and After: Stock Option (right to buy), 13,250 to 9,938 contracts (Direct); Common Stock, 189,543 to 185,543 shares (Direct)

Other Insiders: 5 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (2)

1. F1. The shares were sold in multiple trades at prices ranging from $75.41 to $75.56. The price reported above reflects the weighted average sales price.
2. F2. 25% of the total options vested on each of March 31, 2018, March 31, 2019, March 31, 2020, and March 31, 2021.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did ANIP CFO Stephen P. Carey report on this Form 4?

Stephen P. Carey reported exercising stock options for 3,312 shares at $49.51 each and selling 7,312 common shares in open‑market trades. The sales occurred at prices around $75.42 and $75.56 on March 5, 2026, reflecting a net reduction in his share holdings.

How many ANI Pharmaceuticals (ANIP) shares does the CFO hold after the reported trades?

After the reported transactions, Stephen P. Carey directly holds 185,543 shares of ANI Pharmaceuticals common stock. He also continues to hold 9,938 stock options following the March 5, 2026 option exercise, according to the totals reported in the Form 4 transaction tables.

At what prices did ANIP CFO Stephen P. Carey sell his shares on March 5, 2026?

Stephen P. Carey sold 3,312 common shares at a weighted average price of $75.42 and another 4,000 shares at $75.56. A footnote explains the 3,312‑share block was executed in multiple trades between $75.41 and $75.56, with $75.42 reported as the weighted average.

What stock option activity did ANIP’s CFO report in this Form 4 filing?

The filing shows Stephen P. Carey exercised a stock option for 3,312 shares at $49.51 per share. The option had previously vested in four 25% installments on March 31 of 2018, 2019, 2020, and 2021. After this exercise, 9,938 options remain outstanding.

Was the ANIP CFO’s share sale in this Form 4 an open‑market transaction?

Yes, the Form 4 identifies both 7,312 shares sold by Stephen P. Carey as open‑market or private sales, using transaction code S. The description specifies these were sales in the open market or private transactions, with pricing details provided for the 3,312‑share trade block.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CAREY STEPHEN P.

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

210 MAIN STREET WEST

(Street)

BAUDETTE MN 56623

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP & CFO

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/05/2026		M		3,312	A	$49.51	192,855	D
Common Stock	03/05/2026		S		3,312	D	$75.42(1)	189,543	D
Common Stock	03/05/2026		S		4,000	D	$75.56	185,543	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$49.51	03/05/2026		M			3,312	(2)	03/30/2027	Common Stock	3,312	$49.51	9,938	D

Explanation of Responses:

1. The shares were sold in multiple trades at prices ranging from $75.41 to $75.56. The price reported above reflects the weighted average sales price.

2. 25% of the total options vested on each of March 31, 2018, March 31, 2019, March 31, 2020, and March 31, 2021.

Remarks:

	/s/ Stephen P. Carey, by attorney-in-fact Meredith W. Cook	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.